 Anti-bronchoconstriction 2-(4'-pyridinyl)-thiazole derivatives, composition, and method of use therefor |
| We claim: 1. A compound having the structural formula I ##STR4## wherein R is cyano, ##STR5## --C(.... |
|
| Antioxidant-induced apoptosis in vascular smooth muscle cells |
| The invention is based on the discovery that, unlike other cell types, vascular smooth muscle cells ... |
|
| Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors |
| In a method aspect, this invention relates to a method of treating the climacterium symptoms in a ... |
|
| Microbial hair tonic composition |
| We claim: 1. A microbial hair treatment composition comprising 10.sup.6 to 10.sup.8 cells/ml of ... |
|
| Hair treating composition |
| OF THE INVENTION The formulation of 9 parts d-panthenyl ethyl ether and 1 part d-panthenol can be ... |
|
| Hair cosmetic composition |
| We claim: 1. A composition of matter in the form of a solution, comprising: (a) a solvent including ... |
|
| Anti-thrombogenic, anti-microbial compositions containing heparin |
| OF THE INVENTION The compositions of the present invention are first dissolved in solvent mixtures ... |
|
| Derivative-compound-conjugates and pharmaceutical compositions comprising same |
| OF THE INVENTION The introduction of molecules of diagnostic, prophylactic, or therapeutic ... |
|
| Vincamine derivatives and process for the preparation of vincamine and derivatives thereof |
| Having now described our invention what we claim as new and desire to secure by Letters Patent is: 1... |
|
|
Method of use of bicycloheptane substituted prostaglandin analogs as cardiovascular agents
| Details |
Inventors: Sprague, Peter W.; Loots, Melanie J.; Haslanger, Martin F.;
Assignee: E. R. Squibb & Sons, Inc. (Princeton, NJ)
Primary Examiner:
Assistant Examiner:
Attorney, Agent or Firm:
Bicycloheptane substituted prostaglandin analogs are provided having the structural formula ##STR1## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A method of inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, which comprises administering to the circulatory system of a mammalian host an effective amount of a compound having the structural formula ##STR13## and including all stereoisomers thereof; wherein A is --CH.
sub.
2 --CH.
sub.
2 or --CH.
dbd.
CH--; m is 0 to 5; B is --CH.
dbd.
CH-- or (CH.
sub.
2).
sub.
2 ; R is H, lower alkyl, alkali metal or tris(hydroxymethyl)aminomethane; and R.
sup.
1 is aralkyl, cycloalkyl or cycloalkylalkyl or a pharmaceutically acceptable salt thereof.
2.
The method as defined in claim 1 wherein said compound is administered in an amount within the range of from about 1 to about 100 mg/kg.
3.
The method as defined in claim 1 where in said compound A is CH.
dbd.
CH.
4.
The method as defined in claim 1 where in said compound B is CH.
dbd.
CH.
5.
The method as defined in claim 1 where in said compound B is --CH.
sub.
2 CH.
sub.
2 --.
6.
The method as defined in claim 1 where in said compound R.
sup.
1 cycloalkyl.
7.
The method as defined in claim 1 where in said compound R.
sup.
1 is aralkyl.
8.
The method as defined in claim 1 wherein said compound has the name [1.
alpha.
,2.
beta.
(Z),3.
beta.
(1E,4S),4.
alpha.
]-7-[3-(3-hydroxy-4-phenyl-1-p entenyl)bicyclo[2.
2.
1]hept-2-yl]-5-heptenoic acid or the methyl or ethyl ester thereof, including all stereoisomers thereof.
9.
The method as defined in claim 1 wherein said compound has the name [1.
alpha.
,2.
beta.
(Z),3.
beta.
(1E),4.
alpha.
]-7-[3-(3-cyclohexyl-3-hydroxy-1- propenyl)bicyclo[2.
2.
1]hept-2-yl]-5-heptenoic acid including all stereoisomers thereof.
10.
A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host an effective amount of a compound having the structural formula ##STR14## and including all stereoisomers thereof; wherein A is --CH.
sub.
2 --CH.
sub.
2 or --CH.
dbd.
CH--; m is 0 to 5; B is --CH.
dbd.
CH-- or (CH.
sub.
2).
sub.
2 ; R is H, lower alkyl, alkali metal or tris(hydroxymethyl)aminomethane; and R
|
| Related patents |
|
|
1-arylsulphonyl-2-piperidinone derivatives, process and intermediates for the preparation thereof, their application as antispasmodics and compositions containing them
What is claimed is: 1. The compound of formula (I): ##STR11## in which R represents the radical ##STR12## in which R.sub.1 at any position on the benzene ring represents ...
|
|
|
Dihydropyridine derivatives and pharmaceutical composition thereof
OF THE INVENTION This invention relates to dihydropyridine derivatives represented by the formula (I) ##STR2## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or ...
|
|
|
1-[2-(1H-inden-3-yl)ethyl]-4-(naphth-1-yl)piperazine derivatives, their preparation and their application in therapeutics
We claim: 1. A compound of the formula: ##STR6## in which X represents a hydrogen atom, a C.sub.1 -C.sub.3 alkoxy group or a cyclopropylmethoxy group, and Y represents a ...
|
|
|
Use of fedotozine in the treatment of functional states of intestinal obstructions
We claim: 1. Process for inhibiting functional ileus in a patient, which consists of administering a therapeutically effective dose of (+)-1-[(3,4,5-trimethoxy)...
|
|
|
Manufacture of pharmaceutical dosage forms
OF THE INVENTION The present invention is directed to solid, unit dosage forms primarily for oral ingestion which are advantageous in a number of particulars over ...
|
|
|
Device comprising liner for protecting fluid sensitive medicament
OF THE DRAWING FIGURES Turning now to the drawings in detail, which are examples of various delivery devices provided by the invention and which examples are not to be ...
|
|
|
In situ active compound assembly
I claim: 1. A method to modify a target condition contained within an environment with a conjugate active in modifying said target condition which conjugate comprises at ...
|
|
|
Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
The invention is directed to a method for the prophylaxis or treatment of an animal for systemic hypotension or other pathogenic syndromes induced by inappropriate ...
|
|
|
Use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension
The present invention involves a method for prophylaxis or treatment of an animal for systemic hypotension induced by endotoxin and/or a biological response modifier ...
|
|
|
Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
The inventors herein propose uses of anti-TNF antibodies, anti-endotoxin antibodies, and cytokine receptor antagonists (e.g., IL-1 receptor antagonist) in combination ...
|
|
|
Vasodialators 
